MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaip.2026.08.023

Медицинская библиотека · The journal of allergy and clinical immunology. In practice · 2026

Recombinant Aspergillus fumigatus-Specific IgE for Monitoring Treatment Response and Detecting Exacerbations in Allergic Bronchopulmonary Aspergillosis.

Muthu Valliappan, Kaur Renu, Singh Mani, Sehgal Inderpaul Singh, Dhooria Sahajal, Prasad Kuruswamy Thurai, Rudramurthy Shivaprakash M, Aggarwal Ashutosh Nath, Chakrabarti Arunaloke, Agarwal Ritesh

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Serum total IgE is the preferred biomarker for monitoring disease activity in allergic bronchopulmonary aspergillosis (ABPA). The utility of IgE directed against recombinant Aspergillus fumigatus antigens (rAsp-IgE) for monitoring treatment response and detecting exacerbations in ABPA remains unknown.

OBJECTIVE

To evaluate longitudinal changes in rAsp-IgEs during treatment of ABPA, compare their performance with serum total IgE and crude A. fumigatus-specific IgE (cAsp-IgE), and assess the utility of rAsp-IgEs for detecting ABPA exacerbations.

METHODS

We prospectively enrolled consecutive adults with ABPA. Serum total IgE, cAsp-IgE, and rAsp-IgEs (f1, f2, and f4) were measured at baseline, 2, and 4 months of treatment. We assessed the proportion of participants achieving a ≥20% decline in each biomarker. Participants were followed for 12 months to identify exacerbations and evaluate biomarker behavior.

RESULTS

Among 122 enrolled participants, 119 and 107 completed the 2- and 4-month assessments. Serum total IgE and all 3 rAsp-IgEs declined significantly at both time points, whereas cAsp-IgE showed no significant decline. A ≥20% decline in at least one rAsp-IgE occurred more frequently than that in serum total IgE at 2 (91.6% vs 77.1%; P = .003) and 4 months (88.8% vs 74.8%; P = .007). Fifteen participants experienced exacerbations; rAsp f4-IgE increased in all events (100%) compared with total IgE (12 of 15, 80%), rAsp f1-IgE (7 of 15, 46.7%), and rAsp f2-IgE (6 of 15, 40%).

CONCLUSIONS

rAsp-IgEs demonstrated significant longitudinal declines during ABPA treatment, whereas rAsp f4-IgE consistently increased during exacerbations. Larger multicenter prospective studies are warranted to define their role in disease monitoring.

Для цитирования: Muthu Valliappan, Kaur Renu, Singh Mani, Sehgal Inderpaul Singh, Dhooria Sahajal, Prasad Kuruswamy Thurai, Rudramurthy Shivaprakash M, Aggarwal Ashutosh Nath, Chakrabarti Arunaloke, Agarwal Ritesh. Recombinant Aspergillus fumigatus-Specific IgE for Monitoring Treatment Response and Detecting Exacerbations in Allergic Bronchopulmonary Aspergillosis.. The journal of allergy and clinical immunology. In practice. 2026. DOI: 10.1016/j.jaip.2026.08.023.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.